ANGLE PLC (LON:AGL) (OTCQX:ANPCY) has announced that independent data from researchers at The University of Texas MD Anderson Cancer Center, published in the peer-reviewed journal PLOS ONE, demonstrates the performance of ANGLE’s Parsortix system in tandem with multiple downstream molecular characterisation of circulating tumour cells (CTCs).
The world-leading liquid biopsy company noted that the study used blood from healthy volunteers spiked with cancer cells from five breast cancer cell lines and one lung cancer cell line to evaluate the linearity, sensitivity, and specificity of the Parsortix system in combination with three downstream techniques for the molecular characterisation of CTCs.
The Parsortix system demonstrated strong linearity suggesting that a patient sample would reflect the frequency of CTCs in the patient’s blood. Furthermore, the system was shown to be capable of isolating a single CTC spiked into 5mL of blood. This is significant given the rarity of CTCs and the prognostic significance of even a single CTC during adjuvant treatment of breast cancer, ANGLE said.
READ: ANGLE raises around GBP20mln in new investment that will propel the business into the next phase of development
Using gene expression analysis methods (qRT-PCR), the authors detected gene transcripts at high sensitivity from as few as five spiked cancer cells or less. In addition, the HTG EdgeSeq nuclease protection assay, was able to profile RNA expression of over 2,500 cancer-related genes from the Parsortix system enriched cells. Such downstream analysis has the potential to provide actionable clinical insight and personalised medicine with corresponding targeted therapies as exemplified in this study by quantification of HER2 and PD-L1.
Whilst CTC enumeration is highly prognostic, molecular characterisation of CTCs has the potential to inform individualised treatment strategies and provides a repeatable minimally invasive means to monitor disease and provide targeted treatment over time.
ANGLE said this study provides further evidence that the Parsortix system is able to capture and harvest a variety of CTCs, irrespective of their surface antigens, for downstream molecular analysis. Critically, unlike the legacy antibody-based CTC system, the Parsortix system was able to isolate and harvest mesenchymal CTCs which are known to have prognostic significance and metastatic propensity.
Breast cancer is the most frequently diagnosed cancer in women with 2 million cases diagnosed globally and 240,000 cases diagnosed each year in the US. Every tumour evolves differently with time and treatment, bringing about the need for longitudinal patient monitoring. CTCs as a liquid biopsy, provides for minimally invasive, real-time monitoring of cancer patients, giving comprehensive insight into clonal evolution and the potential to provide actionable information for targeted therapy.
In a statement, ANGLE founder and chief executive, Andrew Newland, commented: “This study demonstrates the key capabilities of the Parsortix system to isolate CTCs for multiple forms of molecular analysis and the potential for the future development of clinical diagnostics to guide individualised treatment strategies. It also further exemplifies the utility of the Parsortix system in isolating breast cancer CTCs, which is the focus for ANGLE’s FDA submission made in September 2020 and currently under substantive review by the FDA. “
MD Anderson Professor and Senior Author James M. Reuben, added: “Here we validated the ability of the Parsortix system to isolate and harvest small numbers of cultured cells spiked into healthy donor blood in combination with downstream molecular characterisation. Harvest of captured rare cells by the Parsortix system followed by analysis using the HTG EdgeSeq assay offers the potential for multimodal characterisation of CTCs, which could be highly advantageous in clinical decision making. Furthermore, molecular characterisation of CTCs, as demonstrated in this study, has potential for the development of minimally-invasive diagnostics.”
The research, which has been published in the peer-reviewed journal PLOS ONE, may be accessed via: https://angleplc.com/library/publications/
In early morning trading, ANGLE shares were 1.3% higher at 42.75p.
— Adds share price —